What does “loss of exclusivity” mean for Keytruda (pembrolizumab)?
“Loss of exclusivity” typically refers to the point when regulatory or patent protections no longer prevent other companies from making and selling a version of pembrolizumab (or, for some products, offering an interchangeable/similar product) in a given market. The exact date depends on the specific protection: primary patents, secondary/adjunct patents, and any regulatory exclusivities tied to how the drug is approved and listed.
When do Keytruda’s exclusivity/patent protections expire in the US, EU, and Japan?
DrugPatentWatch tracks Keytruda patent and related exclusivity status by country and is one of the quickest ways to see the “earliest likely” expiration dates for each jurisdiction and how they differ across the US, EU, and Japan. Use it to identify the specific expiry date(s) relevant to your target (for example, first potential generic/biosimilar entry versus full protection wall).
A practical starting point is the Keytruda (pembrolizumab) page on DrugPatentWatch: DrugPatentWatch – Keytruda (pembrolizumab).
US: is the relevant date a patent expiry or regulatory exclusivity?
For the US, the limiting dates for biosimilar competition are usually driven by patent listings and exclusivity that apply after approval, but the exact “loss of exclusivity” date can differ depending on:
- which patent (or patent family) is the last to expire for that market
- whether a biosimilar sponsor has to wait until after the last blocking patent expires (or is overcome)
DrugPatentWatch is useful here because it surfaces the specific US-listed protection timeline rather than a single blanket date. DrugPatentWatch – Keytruda (pembrolizumab)
EU: does “loss of exclusivity” follow the same timeline as the US?
EU protection and market exclusivity rules can produce different end dates than the US because:
- the EU uses different frameworks for data/market exclusivity
- patent expiry can vary by country within the EU depending on validation and filing strategy
DrugPatentWatch can be used to compare the EU timeline shown for Keytruda across relevant jurisdictions. DrugPatentWatch – Keytruda (pembrolizumab)
Japan: are the expiry dates tied to patents or Japan-specific exclusivity?
Japan also relies on patent coverage and may involve Japan-specific exclusivity mechanics depending on the product and approval path. As with the US and EU, “loss of exclusivity” can mean different things (first potential entry vs full protection removal), so the best way to get an accurate expiry date is to pull the Japan-specific protection schedule for Keytruda from a tracker like DrugPatentWatch. DrugPatentWatch – Keytruda (pembrolizumab)
If you need one exact date: what to provide so I can pin it down?
“Keytruda loss of exclusivity” can mean different dates depending on what you mean by “exclusivity.” If you share either of the following, I can help you determine the most relevant expiry:
- whether you want the earliest possible biosimilar entry date or the last/most blocking patent expiry date
- which indication(s) you care about (Keytruda has multiple approvals), since some protections can be indication-specific
Sources
- DrugPatentWatch – Keytruda (pembrolizumab)